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Abstract: Since the discovery of cisplatin and its potency in anticancer therapy, the development of
metallodrugs has been an active area of research. The large choice of transition metals, oxidation
states, coordinating ligands, and different geometries, allows for the design of metal-based agents
with unique mechanisms of action. Many metallodrugs, such as titanium, ruthenium, gallium,
tin, gold, and copper-based complexes have been found to have anticancer activities. However,
biological application of these agents necessitates aqueous solubility and low systemic toxicity.
This minireview highlights the emerging strategies to facilitate the in vivo application of metallodrugs,
aimed at enhancing their solubility and bioavailability, as well as improving their delivery to tumor
tissues. The focus is on encapsulating the metal-based complexes into nanocarriers or coupling to
biomacromolecules, generating efficacious anticancer therapies. The delivery systems for complexes
of platinum, ruthenium, copper, and iron are discussed with most recent examples.
Keywords: metallodrugs; nanoparticles; dendrimers; nanotubes; liposomes; biomacromolecules;
encapsulation; targeting; micelles
1. Introduction
Cisplatin was the first Food and Drug Administration (FDA)-approved metallodrug for the
treatment of solid tumors. Cisplatin, or cis-diamminedichloroplatinum (II), is a square planar
coordination complex with two chlorine and two amine ligands in cis configuration. The cytotoxic
effects of cisplatin originate from the formation of active cis-[Pt(NH3)2(H2O)2]2+ species that bind to
nuclear DNA distorting the helical structure, and interfere with DNA replication and transcription
inducing cancer cell apoptosis [1,2]. However, the major limitation of cisplatin is the formation of active
species in the systemic circulation. The fast exchange of chloride ligands to water leads to high systemic
toxicity and limits the clinical dose of the drug [3]. Therefore, often sub-therapeutic concentrations of
cisplatin reaching cancer cells leads to minor DNA damage, DNA repair, and eventually might lead to
the growth of resistant cells. Developing platinum-resistance is a major problem in cisplatin-based
therapy [4,5]. Carboplatin and oxaliplatin are second-generation platinum complexes approved by
the FDA for use as anticancer drugs. They are characterized with lower toxicity profiles, broader
spectrum of action, and overcoming resistance in some types of tumors. However, analogous to
cisplatin mechanism of action hampers elimination of all problems associated with Pt(II) therapy.
Therefore “trans” geometries [6–9], polynuclear [10–14], or platinum (IV) prodrugs [15,16] have been
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explored as possible alternatives, but none have yet entered the clinic. Importantly, high efficacy
of platinum paved the way for the development of other transition metal complexes, many with
outstanding cytotoxic properties against cancer cells.
Transition metals form complexes of multiple geometries based on the number of coordination
sites, offering a stereoisomeric diversity higher than carbon. In addition, a synthesis of metallodrugs
requires fewer steps when compared to organic compounds. This is accompanied by a myriad choice
of coordinating ligands [17] facilitating fine-tuning the properties of metal-based complexes [17,18].
The octahedral titanium species cis-diethoxy-bis(1-phenylbutane-1,3-dionato)titanium(IV) [(bzac)2
Ti(OEt)2] (budotitane), was the first non-Pt(II) metal compound that reached clinical trials [19].
Following this, ruthenium-based complexes were explored showing fewer side effects when
compared to platinum-based agents and activity against Pt-resistant cancers [20–22]. Two ruthenium
derivates, imidazolium trans-DMSO-imidazole-tetrachlororuthenate (NAMI-A) and imidazolium
trans-[tetrachlorido(DMSO)(1H-imidazole)ruthenate(III)] (KP-1019), have been tested in clinical
trials [22,23]. KP-1019 showed efficacy towards primary tumors, such as colon cancer, without
triggering systemic toxicity, while NAMI-A was not cytotoxic but demonstrated activity
against metastases. Moreover, NKP-1339 (the sodium salt analogue of KP1019, sodium
trans-[tetrachloridobis(1H-indazole)ruthenate(III)]) has successfully completed a phase I clinical
trial [24]. NKP-1339 is Ru(III) that binds to serum proteins albumin and transferrin, which transport
and deliver the metallodrug to the tumor tissue. Once inside endosomes, NKP-1339 reduces to Ru(II).
Recently, new designs of ruthenium complexes are emerging that include Ru(η5-C5H5) core. This class
of Ru(II) compounds demonstrates enhanced selectivity and effectiveness, for example ruthenium
pyridocarbazole (DW1/2) showed inhibition of protein kinase in vitro [22,25,26]. Other transition
metal complexes include redox-active mono(thiosemicarbazone) copper compounds [27–29],
nucleic acid-targeting gold(I) complex auranofin [30], or osmium(II) arene complexes that act on
mitochondria [31]. Figure 1 shows a few examples of metallodrugs, including platinum, ruthenium,
gallium, and titanium complexes that were found to have anti-cancer activities [32,33].
Inorganics 2019, 7, x FOR PEER REVIEW  2 of 19 
 
Importantly, high efficacy of pla inum paved the way for the develop nt of other transition me al 
complexes, many with outstandin  cytotoxi  properties against cancer cells. 
Transition etals for  co plexes of ultiple geo etries based on the nu ber of coordination 
sites, o fering a stereoiso eric diversity higher than carbon. I  a itio , a synthesis of eta lo rugs 
requires fe er steps hen co pared to organic co pounds. This is acco panied by a yriad c oice 
of coor i ati  li  [ ] f ilit i  fi        
The octahedral titanium species cis-diethoxy-bis(1-phenylbutane-1,3-dionato)titaniu (IV) [(bzac)2 
Ti(OEt)2] (    fi          
Follo i  this, r t i    l  s i  fe  si e effects hen 
co pared to platinu -based agents and activity a ai st t-resistant ca cers [20–22]. o r theniu  
deri at s, i idazoli  trans- S -i i l -t t  (  an  imidazoliu  
trans-[t tr l l ) t te(III)] (KP-1019), have been tested in cl ical trials 
[22,23]. KP-1019 showed efficacy towards primary tu ors, such as colon can er, without triggering 
systemic toxicity, while NAMI-A was not cytotoxic but demonstrated activity agains  metastases. 
Moreover, NKP-1339 (th  sodium salt analogue of KP1019, sodium trans-[tetrachloridobis(1H-
indazole)ruthenate(III)]) has successf lly completed a phase I clinical trial [24]. NKP-1339 is Ru(III) 
th t binds to serum proteins albumin and transfer in, which transport and d liver the metallodrug 
to the tumor tissue. Once inside endosomes, NKP-1339 reduces t  Ru(II). Recently, new designs of 
ruthenium complexes a e emerging that includ  Ru(η5-C5H5) core. This class of Ru(II) compounds 
demonstrates enhanced selectivity and effectiveness, for xampl  ruthenium pyridocarbazole 
(DW1/2) show d inhibition of protein k nase in vitro [22,25,26]. Other transition metal complexes 
include redox-active mono(thi semicarbazone) copp r compounds [27–29], nucleic acid-targeting 
gold(I) complex auranofin [30], or osmium(II) arene complexes that act on mit chondria [31]. Figure 
1 shows a few examples of metallodrugs, including platinum, ruthenium, gallium, and titanium 
complexes tha  were found to have anti-cancer ac ivities [32,33]. 
 
Figure 1. Chemical structures of representative Pt, Ru, Ti, and Ga anticancer drugs. 
However, major challenges in the clinical application of metallodrugs, when delivered via 
conventional intravenous methods, include limited aqueous solubility and short in vivo half-lives, 
resulting in inadequate bioavailability and low accumulation in the tumors. Therefore, many 
approaches have been proposed to address these limitations, and the main strategies focus on 
exploring nanotechnology-based systems [34,35]. This minireview discusses the examples of 
i r . i l t t r s f re resentative Pt, Ru, Ti, and Ga anticancer drugs.
However, major challenges in the clinical application of metallodrugs, when delivered
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half-lives, resulting in inadequate bioavailability and low accumulation in the tumors. Therefore,
many approaches have been proposed to address these limitations, and the main strategies focus on
exploring nanotechnology-based systems [34,35]. This minireview discusses the examples of synthetic
nanoparticles as well as biological carriers used to increase the solubility, reduce the systemic toxicity,
increase cancer-cell delivery, or achieve cancer-specific targeting of metallodrugs.
2. Synthetic Nanocarriers
The important advantages of nano-based systems for drug delivery applications are high
stability, loading capacity, possibility to incorporate hydrophobic or highly toxic drug molecules,
and, depending on the core material used, achieving controlled or sustained drug release. This can
sharply improve the solubility and bioavailability of the drugs, as well as their pharmacokinetics,
while reducing the side effects associated with therapy [36,37]. The nanoparticles can accumulate in
the tumor through the enhanced permeability and retention (EPR) effect [38]. In EPR the nanoparticles
extravasate through the impaired tumor vasculature, and the lack of appropriate lymphatic drainage
leads to their prolonged retention in the tumor tissue. The degree of nanoparticle accumulation in the
tumor via EPR depends on the tumor’s type and size. The most pronounced EPR effect was observed
in pancreatic, colon, breast, and stomach cancers. Also, a higher accumulation of nanoparticles was
found in larger tumors [39].
In addition, the versatility of nanoparticle technologies and coating strategies, allows the design
of nanoparticle systems capable of cancer cell recognition and selective tumor targeting [40–42].
The advantages of nanocarriers heighten the drug payload within the tumor, thereby improving the
therapeutic outcomes. Table 1 summarizes the nanocarrier-based systems for metallodrug delivery
that have entered clinical trials.
Table 1. Representative metallodrug delivery systems that have entered clinical trials.
Delivery
System Active Drug Formulation Clinical Status Tumor Target Identifier
Polymeric
nanoparticles
oxaliplatin AP5346 Phase II Head and Neckcancer NCT00415298
oxaliplatin NC-4016 Phase I Colorectal cancer NCT03168035
cisplatin NC-6004 Phase III Pancreatic cancer NCT03109158
Liposome
cisplatin Lipoplatin Phase I Lung cancer NCT02702700
cisplatin SPI-077 Phase I, II Ovarian, Breast andSkin cancer
NCT01861496
NCT00004083






Nanoparticles iron oxide Ferumoxytol Early Phase I Glioblastoma NCT00660543
Data are gathered from www.clinicaltrials.gov.
2.1. Liposomes
Liposomes, discovered in 1960s, are one of the first nanosized vehicles used in drug delivery
applications. They are spherical vesicles having an aqueous core surrounded by lipid bilayers, a similar
morphology to cellular membranes [43]. Liposomes are ideal to encapsulate hydrophilic drugs in an
aqueous core, but the hydrophobic therapeutics can also be entrapped within a lipid bilayer. Liposomes
are considered one of the most successful drug delivery vehicles to date [44], with several formulations
approved by the FDA for anticancer therapy and available in the clinic [43,45].
The liposomal formulations of cisplatin have been the most studied including LiPlaCis, SPI-77,
L-NDDP, or lipoplatin [46,47]. Lipoplatin has successfully completed Phase I, Phase II, and Phase III
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human clinical trials. It is a liposome with diameter of ~110 nm with long in vivo half-life of ~120 h,
and was found to effectively accumulate into tumors, while reducing major toxicities associated with
cisplatin [48,49]. Tumoral accumulations with up to ten to 200-fold increase versus normal tissue were
reported [48,49]. However, the liposomal formulations did not enhance the clinical efficacy of cisplatin,
possibly due to inadequate release of the drug in the tumor [50].
The liposomal formulations of Ru have also been proposed [51,52] Shen et al. demonstrated
encapsulation of ruthenium polypirydine complex [Ru(phen)2 dppz](ClO4)2 in a liposome
carrier (Lipo-Ru), composed of dipalmitoylphosphatidylcholine (DPPC), cholesterol, and
distearoylphosphatidylethanolamine (DSPE)-PEG (polyethylene glycol). The schematic of the Lipo-Ru
is presented in Figure 2A. The presence of dipyridophenazine (dppz) ligand in the complex served
as a “light switch” that emitted when nitrogen atoms of dppz were exposed to the hydrophobic
environment of the lipid bilayer [51]. Lipo-Ru was an example of a theranostic system, where drug
delivery, as well as imaging studies, can be accomplished using a single platform [53]. The fluorescent
properties of the nanocarrier were demonstrated using confocal imaging of cells incubated with
Lipo-Ru (Figure 2B). The average diameter of Lipo-Ru was 82.53 ± 2.66 nm with Ru loading of 4% [51].
The liposomes were stable under physiological conditions and biologically active. The in vitro studies
using triple negative breast cancer cells demonstrated high cytotoxicity of Lipo-Ru and low IC50 value
of 4 µM.
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2.2. Micelles
Micelles are simple nanostructures formed from amphiphilic molecules, they range in size between
5 and 100 nm, and are considered to be suitable for drug delivery applications [54]. Micelles are
spherical ellipsoid systems that self-assemble in an aqueous environment to form a hydrophobic
monolayer in the core and a polar surface. Micelles disintegrate slowly upon the interaction of polar
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groups with water, which leads to pore formation within the hydrophobic part and effective drug
escape from the core.
Micelles delivering metallodrugs have been investigated [55–60]. One strategy involved the covalent
attachment of the drug directly to the micelle to avoid its premature release in the circulation [55–59].
Sentzel’s group has developed micelles to deliver Pt(II) and Ru(II) complexes to cancer cells [61–64].
They used various lengths of poly[oligo(ethylene glycol) methyl ether methacrylate] (POEGMEMA) and
1,1-di-tert-butyl 3-(2-(methacryloyloxy)ethyl) butane-1,1,3-tricarboxylate (PMAETC) block copolymers
with pendant bidentate carboxylate ligands to form a carboplatin-like complex directly on the
polymer [62]. The length of hydrophobic PMAETC block was varied and micelles with the shortest
PMAETC block showed highest Pt(II) loading of 83%, smallest hydrodynamic diameter of ~77 nm,
faster Pt(II) release, and higher cytotoxicity towards lung cancer cells than micelles with longer
PMAETC blocks. A similar approach was used to prepare ruthenium micelles of RAPTA-C [RuCl2
(p-cymene)-(PTA)] [63]. RAPTA-C limits growth of solid tumor metastases, and its mechanism of
action relies on inducing cancer cell apoptosis by triggering G2/M phase arrest. However, RAPTA-C
suffers from poor delivery efficacy [65]. The amphiphilic polymers containing the water-soluble
1,3,5-phosphaadamantane (PTA) ligand were used to attach RAPTA-C [63]. The polymers were
modified with fluorescein enabling in vitro evaluation of the micelle uptake by cancer cells.
Encapsulation into micelles showed increased cellular uptake of RAPTA-C and a ten-fold increase in
toxicity in ovarian cancer cell lines, when compared to a free drug.
2.3. Polymeric Nanoparticles
Poly(lactic-co-glycolic) acid (PLGA) [66] is an FDA-approved biodegradable slow-releasing
polymer exhibiting a wide range of erosion times [67]. At present, many PLGA-based formulations
are at the pre-clinical stage [68,69]. Recently, PLGA nanoparticles incorporating ruthenium-based
radiosensitizer, Ru(phen)2(tpphz)2+ (phen = 1,10-phenanthroline, tpphz = tetrapyridophenazine)
(Ru1), were investigated as a combination therapy in oesophageal cancer cells [70]. The nanoparticles
were formed via a double emulsion evaporation method from a polymer:drug mixture at the ratio of
1:6.25, respectively, resulting in drug loading of 1.14%. The surface of the nanoparticles was modified
with metal ion chelator diethylenetriaminepentaacetic acid (DTPA) for 111In radiolabelling, and the
targeting ligand for human epidermal growth factor receptor (EGFR). The schematic of the nanoparticle
is shown in Figure 3A. The Ru1 is electron-dense and can be clearly distinguished inside the PLGA
core. The in vitro studies showed higher nanoparticle uptake in EGFR-overexpressing oesophageal
cancer cells, when compared to cells with normal EGFR levels. Importantly, co-delivery of 111In
and Ru1 led to synergistic cytotoxic effects through 111In radiotoxicity and DNA damage fortified
by Ru1 intercalating properties, resulting in enhanced therapeutic outcomes (Figure 3B). In another
approach, Ru(II) was encapsulated into PLGA nanoparticles with a diameter of ~100 nm and evaluated
in two-photon-excited photodynamic therapy (PDT) [71]. The nanoparticles showed cytotoxic effects
in vitro on C6 glioma cells.
Yang et al. coordinated Pt (IV) to diamminedichlorodihydroxyplatinum (DHP) polymer or its
dicarboxyl derivative diamminedichlorodisuccinatoplatinum (DSP) [72]. The platinum(IV)–polymer
conjugates were easily reduced in acidic conditions producing active Pt(II) species. The constructs
were cytotoxic in vitro towards breast (MDA-MB-468, MCF-7) and ovarian cancer (SKOV-3) cell lines,
and in vivo evaluation showed accumulation of the conjugates in the tumor.
Earlier reports on Pt(IV) prodrugs delivery using polymeric carriers include the work of
Dhar et al., where Pt(IV) complex was loaded into PEG-PLGA nanoparticles, and the nanoparticle’s
surface was decorated with aptamer targeting ligand for prostate-specific membrane antigen
(PSMA) [73]. The in vitro studies demonstrated higher cytotoxicity of nanoparticle Pt(IV) formulation
towards prostate cancer cells than the free drug. Furthermore, Aryal et al. conjugated Pt(IV) to PLA of
PEG-PLA block copolymer, using acid labile bonds [74]. The nanoparticles formed from the construct
had an average diameter of about ~100 nm, and showed a controlled acid-responsive drug release.
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Also, Rieter et al. synthesized the nanoparticles by precipitation of disuccinatocisplatin (DSCP) with
Tb3+ ions [75]. The nanoparticles were stabilized with a shell of amorphous silica and showed higher
than cisplatin in vitro cytotoxicity.Inorganic  2019, 7, x FOR PEER REVIEW  6 of 19 
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In another example, Keppler’s group used poly(lactic acid) nanoparticles stabilized with Tween
80 surfactant, as a delivery vehicle for KP1019 [76]. The mean diameter of the nanoparticles was
164 ± 10 nm with ruthenium loading of about 2.4 µmol and 95% loading efficiency. The nanoparticles
were stable for at least 25 days. The in vitro testing with colon carcinoma SW480 and the hepatoma
Hep3B cell lines demonstrated higher cytotoxicity of the formulation versus free KP1019. Interestingly,
the interaction of Ru(III) with Tween 80 led to an exchange of one chlorido ligand and reduction of
Ru(III) to Ru(II), the 20-fold higher in vitro biological activity of the construct was observed.
2.4. Carbon Nanotubes (CNTs)
Carbon nanotubes, high aspect ratio nanomaterials, have been considered as drug delivery
vehicles primarily due to their excellent cellular penetration ability, and hollow interior capable of
incorporating high payloads of drug molecules. The major challenge in biological use of CNTs is their
toxicity. However, large surface area of CNTs and the choice of surface chemistries can potentially
alleviate this problem by introducing additional functionalities to increase biocompatibility [77].
Several carbon nanotube-based carriers have been developed for Pt(IV) prodrug delivery [78–83].
In one example, two different diameters of multi-walled carbon nanotubes were examined to deliver
Pt(IV) to HeLa cells [82]. The cells internalized the CNTs-Pt effectively, with the larger diameter
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CNTs-Pt showing higher cytotoxicity than the smaller one or free drugs. Importantly, low toxicity was
observed after the incubation of CNTs-Pt with murine macrophages.
Zhang et al. encapsulated ruthenium(II) complexes into single-walled carbon nanotubes for
photothermal and photodynamic therapy with near-infrared (NIR) irradiation [84]. Ru(II) complexes,
were sonicated with SWCNTs for 4 h to produce Ru@SWCNTs. The schematic of the construct and
TEM image are shown in Figure 4A. Ru(II) encapsulated into SWCNTs via pi–pi interactions, and Ru(II)
loading was 15.4 µg/mL at SWCNTs concentration of 34.6 µg/mL. The irradiation with an 808 nm
diode laser led to localized photothermal effects due to light absorption by SWCNTs, while released
Ru(II) complexes produced singlet oxygen species (1O2). The synergistic effect led to tumor ablation
in vivo. The thermographs from the in vivo studies are shown in Figure 4B.
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Figure 4. (A) Schematic design of Ru@S CNTs. (B) Thermographs of tumor-bearing mice receiving
photothermal treatment with Ru1@SWCNTs different periods of time (0 to 5 min). Reprinted with
permission from reference [84].
A similar approach was used by Wang et al., where a Ru(II) polypyridyl complex was loaded
in multi-walled carbon nanotubes producing RuPOP@MWCNTs delivery system [85]. The cellular
uptake and efficacy of the construct was evaluated in drug-resistant R-Hep-G2 liver cancer cells.
The RuPOP@MWCNTs entered cells via endocytosis, and higher uptake was observed in cancer cells
than in normal cells. Also, the system was evaluated with clinical X-rays, and resulted in reactive
oxygen species (ROS) overproduction, which induced cancer cell apoptosis.
2.5. Inorganic Nanoparticles
Inorganic nanoparticles have been applied in anticancer therapy as either therapeutic agents
or as carrier vehicles for small drug molecules. Their advantages include unique physicochemical
properties, large surface area, and versatility of surface chemistries for ligand attachment, as well as
biocompatibility [86].
Several groups have studied gold nanoparticles as a delivery system for platinum-based
agents [87–91]. In one example by Xiong et al., cisplatin was complexed onto a gold nanoparticle
modified with tripeptide and a folic acid-PEG linker [87]. The laser irradiation led to Pt (II) release
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either through the ligand exchange with chloride ions, or Au–S bond cleavage and peptide–folate–Pt
conjugate release from the surface of the nanoparticle. The cytotoxic effects were evaluated against
folate-overexpressing human epidermoid carcinoma KB cells, where the nanoparticles showed high
biological activity.
Pramanik et al. also used gold nanoparticles to deliver a copper(II) diacetyl-bis(N4-
methylthiosemicarbazone) complex [92]. The loading strategy involved the attachment of the Cu(II)
complex to the linker containing disulfide bond in the middle and carboxylic acid end. The linker-Cu(II)
was loaded onto the gold nanoparticle surface modified with the amine terminated PEG. The schematic
of the nanoparticle is shown in Figure 5A. In addition, the attachment of biotin on the nanoparticle’s
surface provided cancer specific targeting, as fast proliferating cells demand biotin and often
overexpress the biotin receptors on their surface. The in vitro and in vivo studies showed activity
towards HeLa cells and a HeLa cell xenograft tumor model, respectively. The 3.8-fold reduction in
tumor volume was observed with the Cu(II)-nanoparticle treatment (Figure 5B).
The use of selenium nanoparticles as carrier vehicles for metallodrugs has also been
reported [93,94]. Sun et al. investigated the cytotoxicity of selenium nanoparticles stabilized with
thiolated Ru(II)–polypyridyl complexes [93]. The fluorescent properties of the nanoconstructs allowed
the imaging studies of Ru(II)–Se nanoparticle uptake by cancer cells. The Ru(II)–Se nanoparticles
inhibited tumor growth and angiogenesis in vivo in a xenograft HepG2 tumor model.
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Liu et al. synthesized folic acid-conjugated selenium nanoparticles as a carrier for ruthenium
polypyridyl [94]. Similarly to previous reports, the nanoparticle was modified with folic acid for
cancer cell targeting, and the system exhibited fluorescent properties allowing the imaging of the
nanoparticle trafficking inside the cell. The main goal of this study was to overcome the multidrug
resistance using the proposed nanoparticle system. The in vitro studies with multidrug resistant cells
R-HepG2 demonstrated high toxicity through up-regulating the ROS level inside the cells triggering
mitogen-activated protein kinases (MAPKs) and protein kinase B (AKT) pathways for cancer cell death.
Mesoporous silica nanoparticles also emerged as nanocarriers for metal-based complexes.
The advantages of silica carriers include chemical stability, ease of surface modification with
different functional groups for subsequent drug conjugation, as well as a tunable pore diameter [95].
Gomes-Ruiz’s group employed mesoporous silica nanoparticles as carriers for tin, titanium,
and ruthenium complexes [34,96–103]. Interestingly, they observed that the entire nanostructure
of mesoporous silica–drug conjugate was involved in triggering cancer cell apoptosis, and only a
small release of the encapsulated metallodrug was contributing to cytotoxic effects. This work was
pioneering as it pointed towards a non-classical mechanism of action usually observed for these types
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of systems. This was highlighted in a recent publication by this group, where the complexes of tin and
titanium were immobilized onto silica-based material SBA-15 (Santa Barbara Amorphous-15) modified
with the aminodiol ligand 3-[bis(2-hydroxyethyl)amino] propyltriethoxysilane [102]. This construct
was used as a support to attach diorganotin(IV) compound, SnPh2Cl2, and two titanocene derivatives,
TiCp2Cl2 ([Ti(η5-C5H5)2Cl2] and TiCpCpPhNfCl2 ([Ti(η5-C5H5) (η5-C5H4CHPhNf)Cl2] (Ph = C6H5;
Nf = C10H7). The tin loading was determined to be 12 wt % and titanium 3.2 and 2.0 wt %, respectively.
The pore diameter of mesoporous silica decreased from 5.4 nm to 3.3 nm after the drug conjugation.
The apoptotic effects have been studied in three different cancer cell lines: Human DLD-1 colon
carcinoma, A2780 ovarian carcinoma and A431 epidermoid carcinoma. Although the observed drug
release was low, only 10% of loaded tin and 1% of titanium from the constructs, the cancer cell viability
was markedly reduced. It was found that silica-tin nanostructures induce apoptosis through the
Fas–FasL system while silica-titanium constructs interfere with the TNF-α pathway. Therefore, it was
concluded that the factors contributing to cancer cell death were small release of metallodrug from
mesoporous silica as well as the presence of the nanoconstruct itself.
Other groups have investigated biomimetic hydroxyapatite nanocrystals as the delivery
vehicles for platinum (II) [104–106]. The advantage of hydroxyapatite nanostructures is their
intrinsic biocompatibility with biological systems since they are mineral constituents of bone [107].
For example, Natile’s group used hydroxyapatite nanocrystals to deliver two platinum derivatives
of cis-1,4-diaminocyclohexane ([PtX2(cis-1,4-DACH)], X2 = Cl2 and 1,1-cyclobutanedicarboxylate
(CBDCA) [105]. The complexes were adsorbed on the surface of the nanocrystals and the
systems were tested in different cancer cell cultures. The in vitro studies included human colon
(LoVo) and lung (A549) cancer cells as well as human osteosarcoma cells sensitive (U2OS) and
resistant (U2OS/Pt) to cisplatin. The release of the complexes was accelerated at lower pH
associated with the tumor’s microenvironment, upon dissolution of hydrohyapatite nanocrystals.
The hydroxyapatite-PtX2(cis-1,4-DACH) nanoconstruct has proven to be more cytotoxic than the other
derivative, primarily due to its fast release from the nanocrystals.
2.6. Dendrimers
Dendrimers are nanoscale macromolecules that have a spherical three-dimensional morphology
and are formed by a successive addition of layers of branching groups. The step-wise synthesis of
dendrimers provides the control over the number of branches, producing different generations of
the dendrimers with distinct size and molecular weight. The external layer of the dendrimer has
functional groups that can provide solubility or serve as an anchoring site to attach additional ligands.
The drug molecules can be encapsulated in the interior of the branches or attached to the surface
groups. Dendrimers can be composed of any type of monomer, and thus a variety of dendrimers exists,
with many showing low cytotoxicity profiles while applied in biological settings [108].
Dendrimers have been investigated for the delivery of metallocomplexes [109–114]. For example,
Gouveia et al. produced low generation dendrimers modified with an organometallic compound
of Ru(II) [110]. The nitrile poly(alkylidenimine) dendritic scaffolds of different sizes were modified
with an organometallic fragment [Ru(η5-C5H5)(PPh3)2]+ attached to the peripheral end groups of the
dendrimers. The Ru(II)-dendrimers showed high biological activity in vitro against different cancer
cell lines, such as Caco-2 (colon adenocarcinoma), CAL-72 (osteocarcoma), and MCF-7 (breast cancer).
In addition, the metallodendrimers showed cytotoxicity higher than cisplatin in ovarian A2780 cells
and A2780-platinum resistant cells.
In another example, Smith’s group studied organometallic dendrimers of diaminobutane
containing ruthenium(II)–p-cymene, ruthenium(II)–hexamethylbenzene, rhodium(III)-cyclopentadienyl,
and iridium(III)–cyclopentadienyl moieties [113]. The biological activity of the metallodendrimers was
evaluated in vitro using A2780 cisplatin-sensitive and A2780cisR cisplatin-resistant human ovarian
cancer cell lines as well as a non-tumorigenic HEK-293 human embryonic kidney cell line. All constructs
showed cytotoxicity but the most pronounced effects were observed for ferrocenyl-derived
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ruthenium(II)–hexamethylbenzene metallodendrimer. Importantly, all metallodendrimers showed
lower cytotoxicity towards non-malignant cells. Interestingly, it was proposed that the possible mode
of action of these constructs might involve non-covalent interactions with DNA.
Li et al. formulated supramolecular dendritic system for Pt(II) delivery (Figure 6). The building
blocks included the lipoic acid functionalized dendrons, Pt(II)–PEG conjugate, and a NIR fluorophore
for in vivo imaging purposes [114]. The core was bridged via disulfide bonds and incorporated
Cy5.5 dye, while Pt(II)–PEG conjugate was attached to the terminal carboxyl groups of lipoic acid.
Pt(II) formed carboplatin-like complex with the carboxyl groups of the acid, and PEG moiety provided
the shell of the nanoplatform. The in vitro studies with lung adenocarcinoma A549 cells showed
internalization of the nanostructures via endocytosis and high cytotoxicity, while in vivo studies
demonstrated efficacy comparable to cisplatin with avoiding the nephrotoxicity. NIR imaging revealed
the localization of nanostructures in vitro and in vivo facilitating the determination of Pt(II) delivery
to target sites.
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3. Biological Carriers
Natural biomacromolecules, such as proteins and peptides, are attractive carriers for small drug
molecules due to their inherent biodegradability, biocompatibility, low toxicity, and high aqueous
solubility. Additionally, biological drug carriers can recognize tumor markers overexpressed by cancer
cells, which has been readily used in targeted therapies. Finally, peptides and proteins are easy to
manufacture and stable, which is often challenging to accomplish with synthetic nanoparticles [115].
3.1. Peptides
The delivery of metallodrugs using peptides as biological carriers has been investigated.
Wlodarczyk et al. used the SV40 large T antigen-derived PKKKRKV peptide known as nuclear
localization sequence (NLS) peptide, as a carrier to deliver Pt(II) therapy [116]. The NLS peptide
is a recognition signal on proteins facilitating the nuclear transport of biomolecules. In the study,
the N-terminal of the NLS peptide was modified with malonic acid derivative during the solid-state
peptide synthesis, and the carboplatin-like complex was formed directly on the peptide from activated
Pt(II). The schematic of the construct is presented in Figure 7A. The solubility of the Pt-NLS hybrid
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was 50 mg/mL, which was much higher than that of native carboplatin (10 mg/mL). The construct
was found to effectively translocate through the cellular membrane (Figure 7B) and deliver platinum
to the nucleus. Importantly, the Pt-NLS hybrid showed high biological activity in ovarian cancer cell
lines, overcoming platinum resistance. This can be attributed to higher Pt(II) content in the resistant
cells. The quantification of Pt(II) in the nucleus from two isogenic A2780 (Pt sensitive) and CP70 (Pt
resistant) cells showed that in A2780 cells one Pt(II) was attached every 20th DNA turn, while in CP70
cells every 10th turn.
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Similarly, Noor et al. used the NLS peptide to form ferrocene–NLS conjugate [117]. The ferrocene
carboxylic acid was attached to the N-terminus of the NLS peptide. The evaluation of the conjugate
with Hep G2 cells did not show the cytotoxic effects. However, the presence of metallocene moiety
increased the cellular uptake of the construct, which can potentially serve as a platform to add
additional functionalities. The same group tested the cobaltocenium–NLS conjugates prepared using
the same approach, and also observed the enhanced cellular accumulation of the construct [118].
Inorganics 2019, 7, 2 12 of 19
3.2. Antibodies and Proteins
Antibody–drug conjugates (ADC) represent a highly potent class of therapeutics that combines
precise cancer cell recognition by monoclonal antibodies mAb with cell killing by small molecule drugs.
The ADC conjugates with metallodrugs have also been developed. Recently, Gupta et al. reported a
Pt(II)-based linker that can re-bridge the inter-chain cysteines in the antibody [119]. The schematic of
the construct is shown in Figure 8A. This strategy resulted in ADC-Pt(II) constructs with higher stability
than conventional ADCs connected via maleimide-based chemistry, reducing the drug exchange with
blood serum albumin and off-target toxicity. The ADC-Pt(II) demonstrated high toxicity in vitro,
and the in vivo studies using the A549 non-small cell lung cancer model showed marked tumor growth
inhibition (Figure 8B) with up to ~80% of apoptotic cells in tumor sections. This novel technology can
be extended to various types of antibodies with a potential to target multiple malignancies.
Hanif et al. demonstrated the functionalization of Ru(II) (arene) complexes with maleimide.
The complexes alone were characterized in vitro with human ovarian (CH1), colon (SW480),
and non-small cell lung cancer (A549) cells, and showed high biological activity. The complexes
were attached to thiolated biomolecules, such as Cysteine (Cys), glutathione (GSH), N-acetylcysteine
(NAC), and N-acetylcysteine methyl ester (N-AcCysMe), as well as human serum albumin
(HSA) [120]. The coupling of the complexes to biomolecules was fast and was completed within
1 h, while binding to HSA occurred in 72 h. These results demonstrate an effective approach to attach
the maleimide-modified metallodrugs to Cys-containing carrier biomolecules.
In A different approach, Zhang et al. studied the delivery of vanadocene dichloride
(Cp2VCl2) using human serum transferrin (h-Tf) and apotransferrin (apo-Tf) plasma proteins [121].
The transferrin protein has two Fe(III) binding sites and its primary role is to transport iron. It was
demonstrated that Cp2VCl2 could bind with h-Tf/apo-Tf by noncovalent conjugation at pH 7.4 and 4.8.
Moreover, the conjugates showed dose-dependent cytotoxicity towards human lung adenocarcinoma
cell line A549. Interestingly, higher cytotoxicity was observed for the vanadocene–protein conjugates
than for the free complex.
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4. Conclusions
In summary, nanocarriers have proven to be powerful tools in enhancing the delivery of
metallordrugs to cancer cells. Nanotechnology offers versatility in nanostructure synthesis methods and
choice of materials, giving the control over physicochemical properties of the final nanodelivery system.
This also allows encapsulating metallodrugs at sufficient payload, increasing their solubility, limiting
the release in the systemic circulation preventing toxicities, and eventually heightening their efficacy
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in vivo. The main advantage of long-circulating nanocarriers is their accumulation in the tumor via
EPR, which leads to increased drug payloads in the tumor. Moreover, the nanodelivery vehicles can be
decorated with targeting ligands that further enhance the entry into cancer cells via receptor-mediated
endocytosis. Furthermore, incorporating fluorescent dyes to the nanocarriers allows unique theranostic
applications. Another attractive strategy involves conjugation of metallodrugs to biomacromolecules,
such as antibodies or functional peptides. They are cheap, easy to produce, stable, and, most
importantlym inherently biodegradable. Also, superior cancer cell recognition can be achieved
using mAb, which, coupled to metallodrugs, amplifies their intracellular delivery. The biological
carriers might be extended even further to include vitamin-mediated drug targeting [122,123]
or steroid-conjugates [124]. These systems have the potential to evolve into highly efficacious
metallodrug-based therapies.
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